The prognostic value of UHRF-1 and p53 in gastric cancer

dc.contributor.authorBabacan, Nalan A.
dc.contributor.authorEgilmez, Hatice Reyhan
dc.contributor.authorYucel, Birsen
dc.contributor.authorParlak, Ilknur
dc.contributor.authorSeker, Mehmet Metin
dc.contributor.authorKacan, Turgut
dc.contributor.authorBahceci, Aykut
dc.contributor.authorCihan, Sener
dc.contributor.authorAkinci, Bulent
dc.contributor.authorEriten, Berna
dc.contributor.authorKilickap, Saadettin
dc.date.accessioned2019-07-27T12:10:23Z
dc.date.accessioned2019-07-28T09:46:55Z
dc.date.available2019-07-27T12:10:23Z
dc.date.available2019-07-28T09:46:55Z
dc.date.issued2016
dc.department[Babacan, Nalan A. -- Seker, Mehmet Metin -- Kacan, Turgut -- Bahceci, Aykut] Cumhuriyet Univ, Sch Med, Dept Med Oncol, Sivas, Turkey -- [Egilmez, Hatice Reyhan -- Eriten, Berna] Cumhuriyet Univ, Sch Med, Dept Pathol, Sivas, Turkey -- [Yucel, Birsen] Cumhuriyet Univ, Sch Med, Dept Radiat Oncol, Sivas, Turkey -- [Parlak, Ilknur] Cumhuriyet Univ, Sch Med, Dept Internal Med, Sivas, Turkey -- [Cihan, Sener] Okmeydani Educ & Res Hosp, Dept Med Oncol, Istanbul, Turkey -- [Akinci, Bulent] Yildirim Beyazit Univ, Sch Med, Dept Med Oncol, Ankara, Turkey -- [Kilickap, Saadettin] Hacettepe Univ, Sch Med, Dept Med Oncol, Ankara, Turkeyen_US
dc.description.abstractBackground/Aims: This study aimed to examine whether UHRF-1 and p53 overexpression is a prognostic marker for gastric cancer. Patients and Methods: Sixty-four patients with gastric cancer (study group) and 23 patients with gastritis (control group) were evaluated. Immunohistochemistry was used to examine expression of UHRF-1 and p53 in gastric cancers and a control group diagnosed with gastritis. Results: The median age was 63 years (18-83 years) in the study group. UHRF-1 was positive in 15 (23%) patients with gastric cancer and fi ve (21.7%) patients with gastritis (P = 0.559). UHRF1 expression level in gastric cancer is more powerful than in gastritis (P = 0.046). Thirty-seven (61%) patients with gastric cancer and only one patient with gastritis were p53 positive (P < 0.001). After a median follow-up of 12 months (1-110), the 2-year overall survival rates were 55% and 30% in negative and positive p53, respectively (P = 0.084). Also, the 2-year overall survival rates were 45% and 53% in negative and positive UHRF-1, respectively (P = 0.132). Conclusion: According to this study, UHRF-1and p53 were not prognostic factors for gastric cancer, whereas they may have a diagnostic value for differantiating between gastric cancer and gastritis.en_US
dc.description.sponsorshipCumhuriyet University Scientific Research Project Unit [T-522]en_US
dc.description.sponsorshipThe work was supported by grants from Cumhuriyet University Scientific Research Project Unit (T-522), Conflict of Interest: None declared.en_US
dc.identifier.doi10.4103/1319-3767.173755en_US
dc.identifier.endpage29en_US
dc.identifier.issn1319-3767
dc.identifier.issn1998-4049
dc.identifier.issue1en_US
dc.identifier.pmid26831603en_US
dc.identifier.scopus2-s2.0-84955444457en_US
dc.identifier.scopusqualityQ3
dc.identifier.startpage25en_US
dc.identifier.urihttps://dx.doi.org/10.4103/1319-3767.173755
dc.identifier.urihttps://hdl.handle.net/20.500.12418/7595
dc.identifier.volume22en_US
dc.identifier.wosWOS:000372831800004en_US
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherMEDKNOW PUBLICATIONS & MEDIA PVT LTDen_US
dc.relation.ispartofSAUDI JOURNAL OF GASTROENTEROLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectGastric canceren_US
dc.subjectp53 genesen_US
dc.subjectprognosisen_US
dc.subjectsurvivalen_US
dc.subjectUHRF-1 proteinen_US
dc.titleThe prognostic value of UHRF-1 and p53 in gastric canceren_US
dc.typeArticleen_US

Dosyalar